PPL Attracts Fresh Analyst Coverage With Earnings Nine Days Out
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
PPL Corporation has drawn a flurry of new analyst coverage this week, even as options traders hold onto the most defensive positioning the stock has seen in twelve months.
The analyst activity is the most newsworthy development of the past seven days. Truist Securities initiated with a Buy rating and a $41 target on Tuesday. HSBC started coverage with the same Buy rating and a $42 target on Thursday last week. Morgan Stanley, already on the name with an Overweight, lifted its target from $39 to $40 earlier in the month. Barclays is the contrarian note: it trimmed its Overweight target from $41 to $38 in mid-October, though it kept the positive rating intact. The consensus stands at Buy across 11 analysts, with a mean target of $39.72, roughly 13% above the current $35.18 price. Wells Fargo holds the street-high at $44. The broad direction of travel from the analyst community is constructive, with the recent initiations reinforcing rather than questioning the investment case.
Options positioning looks defensive by any measure, though it has eased slightly from its most extreme point earlier in October. The put/call ratio is at 1.73, above the 20-day average of 1.26 and around 1.2 standard deviations above that mean. That is a pullback from the 1.96 reading seen on October 19, which was the 52-week high and the most bearish options stance the market had taken on PPL in at least a year. For context, the PCR sat in a steady 0.96 to 1.09 range for most of September and early October before the sharp pivot toward puts. The pattern is less extreme now but still points to investors paying for downside protection with nine days until the November 6 earnings release.
Short interest at roughly 4.9% of free float has been remarkably stable. The estimated position is around 36.1 million shares, barely changed on the week, and has drifted from a September peak near 38.5 million shares. Borrowing costs have fallen 7% over the week to 0.43%, and borrow availability is exceptionally loose at over 3,400%, meaning there are many more shares available to lend than there are shares currently borrowed. There is no squeeze pressure in the lending market, and the short score of 41 ranks in the 33rd percentile, toward the less-shorted end of the universe.
PPL has underperformed its peers over the past week, rising 1.6% against a median gain of roughly 2.9% for close utility peers. EXC gained 3.9% on the week, EVRG added 2.9%, and DUK rose 2.9%. PPL's own earnings history offers limited drama as a reference point: the last print on August 7 produced a 1.1% gain on the day and a 4% rise over the following five sessions. The factor score picture adds colour: the analyst recommendation diffusion factor ranks in the 95th percentile, reflecting the sweep of fresh Buy initiations; the dividend factor scores at the 91st percentile; earnings and valuation metrics are closer to the middle of the universe.
The P/E multiple has expanded roughly 9% over the past thirty days to 16.9x, and price-to-book has moved up from 1.47 to 1.60 over the same period, a modest re-rating that tracks the stock's nearly 10% monthly gain. The next thing to watch is whether the November 6 print, and the guidance it carries for regulated capital spending across Pennsylvania, Kentucky, and Rhode Island, provides a basis for the analyst community's growing target-price consensus.
Stocks in this article
See the live data behind this article on ORTEX.
Open PPL on ORTEX →How this article was generated
- Generated
- 28 Oct 2026, 18:45
- Data as of
- 28 Oct 2026, 18:44
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.